Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial

Abstract Background and Aims Direct‐acting antiviral therapy for hepatitis C virus (HCV) is effective, but few prospective studies among people with ongoing injecting drug use exist. This study evaluated the efficacy of elbasvir/grazoprevir in people with HCV genotype 1/4 (G1/4) infection and recent...

Full description

Bibliographic Details
Main Authors: Jason Grebely, Phillip Read, Evan B. Cunningham, Martin Weltman, Gail V. Matthews, Adrian Dunlop, Mark Montebello, Marianne Martinello, Rosie Gilliver, Philippa Marks, Tanya L. Applegate, Gregory J. Dore, the DARLO‐C Study Group
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:Health Science Reports
Subjects:
DAA
drug use
hepatitis C
injecting drug users
PWID
treatment
Online Access:https://doi.org/10.1002/hsr2.151

Internet

https://doi.org/10.1002/hsr2.151

Similar Items